Koen P Rovers1, Emma C E Wassenaar2, Robin J Lurvink1, Geert-Jan M Creemers3, Jacobus W A Burger1, Maartje Los4, Clément J R Huysentruyt5, Gesina van Lijnschoten5, Joost Nederend6, Max J Lahaye7, Maarten J Deenen8, Marinus J Wiezer2, Simon W Nienhuijs1, Djamila Boerma2, Ignace H J T de Hingh9,10. 1. Department of Surgery, Catharina Cancer Institute, Eindhoven, The Netherlands. 2. Department of Surgery, St. Antonius Hospital, Nieuwegein, The Netherlands. 3. Department of Medical Oncology, Catharina Cancer Institute, Eindhoven, The Netherlands. 4. Department of Medical Oncology, St. Antonius Hospital, Nieuwegein, The Netherlands. 5. Department of Pathology, Catharina Cancer Institute, Eindhoven, The Netherlands. 6. Department of Radiology, Catharina Cancer Institute, Eindhoven, The Netherlands. 7. Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands. 8. Department of Clinical Pharmacy, Catharina Cancer Institute, Eindhoven, The Netherlands. 9. Department of Surgery, Catharina Cancer Institute, Eindhoven, The Netherlands. ignace.d.hingh@catharinaziekenhuis.nl. 10. GROW-School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands. ignace.d.hingh@catharinaziekenhuis.nl.
Abstract
BACKGROUND: Despite its increasing use, pressurized intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC-OX) has never been prospectively investigated as a palliative monotherapy for colorectal peritoneal metastases in clinical trials. This trial aimed to assess the safety (primary aim) and antitumor activity (key secondary aim) of PIPAC-OX monotherapy in patients with unresectable colorectal peritoneal metastases. METHODS: In this two-center, single-arm, phase II trial, patients with isolated unresectable colorectal peritoneal metastases in any line of palliative treatment underwent 6-weekly PIPAC-OX (92 mg/m2). Key outcomes were major treatment-related adverse events (primary outcome), minor treatment-related adverse events, hospital stay, tumor response (radiological, biochemical, pathological, ascites), progression-free survival, and overall survival. RESULTS: Twenty enrolled patients underwent 59 (median 3, range 1-6) PIPAC-OX procedures. Major treatment-related adverse events occurred in 3 of 20 (15%) patients after 5 of 59 (8%) procedures (abdominal pain, intraperitoneal hemorrhage, iatrogenic pneumothorax, transient liver toxicity), including one possibly treatment-related death (sepsis of unknown origin). Minor treatment-related adverse events occurred in all patients after 57 of 59 (97%) procedures, the most common being abdominal pain (all patients after 88% of procedures) and nausea (65% of patients after 39% of procedures). Median hospital stay was 1 day (range 0-3). Response rates were 0% (radiological), 50% (biochemical), 56% (pathological), and 56% (ascites). Median progression-free and overall survival were 3.5 months (interquartile range [IQR] 2.5-5.7) and 8.0 months (IQR 6.3-12.6), respectively. CONCLUSIONS: In patients with unresectable colorectal peritoneal metastases undergoing PIPAC-OX monotherapy, some major adverse events occurred and minor adverse events were common. The clinical relevance of observed biochemical, pathological, and ascites responses remains to be determined, especially since radiological response was absent.
BACKGROUND: Despite its increasing use, pressurized intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC-OX) has never been prospectively investigated as a palliative monotherapy for colorectal peritoneal metastases in clinical trials. This trial aimed to assess the safety (primary aim) and antitumor activity (key secondary aim) of PIPAC-OX monotherapy in patients with unresectable colorectal peritoneal metastases. METHODS: In this two-center, single-arm, phase II trial, patients with isolated unresectable colorectal peritoneal metastases in any line of palliative treatment underwent 6-weekly PIPAC-OX (92 mg/m2). Key outcomes were major treatment-related adverse events (primary outcome), minor treatment-related adverse events, hospital stay, tumor response (radiological, biochemical, pathological, ascites), progression-free survival, and overall survival. RESULTS: Twenty enrolled patients underwent 59 (median 3, range 1-6) PIPAC-OX procedures. Major treatment-related adverse events occurred in 3 of 20 (15%) patients after 5 of 59 (8%) procedures (abdominal pain, intraperitoneal hemorrhage, iatrogenic pneumothorax, transient liver toxicity), including one possibly treatment-related death (sepsis of unknown origin). Minor treatment-related adverse events occurred in all patients after 57 of 59 (97%) procedures, the most common being abdominal pain (all patients after 88% of procedures) and nausea (65% of patients after 39% of procedures). Median hospital stay was 1 day (range 0-3). Response rates were 0% (radiological), 50% (biochemical), 56% (pathological), and 56% (ascites). Median progression-free and overall survival were 3.5 months (interquartile range [IQR] 2.5-5.7) and 8.0 months (IQR 6.3-12.6), respectively. CONCLUSIONS: In patients with unresectable colorectal peritoneal metastases undergoing PIPAC-OX monotherapy, some major adverse events occurred and minor adverse events were common. The clinical relevance of observed biochemical, pathological, and ascites responses remains to be determined, especially since radiological response was absent.
Authors: Lieke G E M Razenberg; Valery E P P Lemmens; Victor J Verwaal; Cornelis J A Punt; Pieter J Tanis; Geert-Jan Creemers; Ignace H J T de Hingh Journal: Eur J Cancer Date: 2016-08-03 Impact factor: 9.162
Authors: Jan Franko; Qian Shi; Jeffrey P Meyers; Timothy S Maughan; Richard A Adams; Matthew T Seymour; Leonard Saltz; Cornelis J A Punt; Miriam Koopman; Christophe Tournigand; Niall C Tebbutt; Eduardo Diaz-Rubio; John Souglakos; Alfredo Falcone; Benoist Chibaudel; Volker Heinemann; Joseph Moen; Aimery De Gramont; Daniel J Sargent; Axel Grothey Journal: Lancet Oncol Date: 2016-10-12 Impact factor: 41.316
Authors: Wiebke Solass; Aurélie Herbette; Tina Schwarz; Alexander Hetzel; Jian-Sheng Sun; Marie Dutreix; Marc A Reymond Journal: Surg Endosc Date: 2011-11-01 Impact factor: 4.584
Authors: Wiebke Solass; Reinhold Kerb; Thomas Mürdter; Urs Giger-Pabst; Dirk Strumberg; Clemens Tempfer; Jürgen Zieren; Matthias Schwab; Marc André Reymond Journal: Ann Surg Oncol Date: 2013-09-05 Impact factor: 5.344
Authors: Stefano Rotolo; Andrea Di Giorgio; Marco Cintoni; Emanuele Rinninella; Marta Palombaro; Gabriele Pulcini; Carlo Alberto Schena; Vito Chiantera; Giuseppe Vizzielli; Antonio Gasbarrini; Fabio Pacelli; Maria Cristina Mele Journal: Pleura Peritoneum Date: 2022-03-01
Authors: Olivia Sgarbura; Clarisse Eveno; Mohammad Alyami; Naoual Bakrin; Delia Cortes Guiral; Wim Ceelen; Xavier Delgadillo; Thanh Dellinger; Andrea Di Giorgio; Amaniel Kefleyesus; Vladimir Khomiakov; Michael Bau Mortensen; Jamie Murphy; Marc Pocard; Marc Reymond; Manuela Robella; Koen P Rovers; Jimmy So; S P Somashekhar; Clemens Tempfer; Kurt Van der Speeten; Laurent Villeneuve; Wei Peng Yong; Martin Hübner Journal: Pleura Peritoneum Date: 2022-03-01
Authors: Jamila Laoukili; Alexander Constantinides; Emma C E Wassenaar; Sjoerd G Elias; Danielle A E Raats; Susanne J van Schelven; Jonathan van Wettum; Richard Volckmann; Jan Koster; Alwin D R Huitema; Simon W Nienhuijs; Ignace H J T de Hingh; René J Wiezer; Helma M U van Grevenstein; Inne H M Borel Rinkes; Djamila Boerma; Onno Kranenburg Journal: Br J Cancer Date: 2022-02-22 Impact factor: 9.075
Authors: Robin J Lurvink; Paulien Rauwerdink; Koen P Rovers; Emma C E Wassenaar; Maarten J Deenen; Joost Nederend; Clément J R Huysentruyt; Iris van 't Erve; Remond J A Fijneman; Erik J R J van der Hoeven; Cornelis A Seldenrijk; Alexander Constantinides; Onno Kranenburg; Maartje Los; Karin H Herbschleb; Anna M J Thijs; Geert-Jan M Creemers; Jacobus W A Burger; Marinus J Wiezer; Simon W Nienhuijs; Djamila Boerma; Ignace H J T de Hingh Journal: BMJ Open Date: 2021-03-30 Impact factor: 2.692
Authors: Robin J Lurvink; Koen P Rovers; Emma C E Wassenaar; Checca Bakkers; Jacobus W A Burger; Geert-Jan M Creemers; Maartje Los; Floortje Mols; Marinus J Wiezer; Simon W Nienhuijs; Djamila Boerma; Ignace H J T de Hingh Journal: Surg Endosc Date: 2021-11-10 Impact factor: 3.453
Authors: Anne G W E Wintjens; Geert A Simkens; Peter-Paul K H Fransen; Narcis Serafras; Kaatje Lenaerts; Gregor H L M Franssen; Ignace H J T de Hingh; Patricia Y W Dankers; Nicole D Bouvy; Andrea Peeters Journal: Clin Exp Metastasis Date: 2022-06-23 Impact factor: 4.510